Charles Ludivico, MD
Rheumatology · Fountain Hill, PANPI 1750439147
Payments from drug & device makers
Across 753 payments — averaging $730.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$205K
- AbbVie$133K
- Gilead$65K
- Argenx US, Inc.$35K
- E.r. Squibb & Sons, L.L.C.$26K
- Lilly USA, LLC$25K
- plus $61K from 28 others
Across 5 payments — averaging $535.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Consulting fees$6,88518%
- Speaking & faculty fees$17,77547%
- Travel & lodging$2,4877%
- Food & beverage$10,70128%
- Education$3141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 32 | $205,306 |
| AbbVie | 200 | $133,056 |
| Gilead | 28 | $65,125 |
| Argenx US, Inc. | 30 | $34,764 |
| E.r. Squibb & Sons, L.L.C. | 41 | $25,549 |
| Lilly USA, LLC | 49 | $25,255 |
| Novartis | 43 | $25,166 |
| Pfizer | 68 | $23,939 |
| Janssen Research & Development, LLC | 2 | $3,757 |
| Bristol Myers Squibb | 4 | $2,935 |
| Amgen | 78 | $1,297 |
| GSK | 36 | $814 |
| Johnson & Johnson(2 entities) | 30 | $661 |
| AstraZeneca(2 entities) | 25 | $606 |
| Radius Health, Inc. | 14 | $546 |
| UCB, Inc. | 15 | $418 |
| Mallinckrodt Hospital Products Inc. | 10 | $245 |
| Organon | 10 | $197 |
| Genentech USA, Inc. | 10 | $170 |
| Aurinia Pharma U.S., Inc. | 5 | $91 |
| Sobi, Inc | 4 | $76 |
| Fresenius Kabi USA, LLC | 3 | $55 |
| Kyowa Kirin, Inc. | 2 | $53 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Actelion Pharmaceuticals US, Inc. | 2 | $52 |
| Invivyd Inc | 1 | $47 |
| Sanofi | 1 | $29 |
| Cumberland Pharmaceuticals, Inc. | 2 | $24 |
| Oxford Immunotec USA Inc | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Sandoz | 1 | $23 |
| Antares Pharma, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$550,408 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 84 | $905,925 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $399,766 |
| Enbrel SureclickEtanercept | 23 | $209,746 |
| XeljanzTofacitinib Citrate | 34 | $174,786 |
| Xeljanz XrTofacitinib Citrate | 23 | $150,372 |
| OrenciaAbatacept | 21 | $133,621 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 13 | $85,913 |
| RinvoqUpadacitinib | 12 | $74,917 |
| Hydroxychloroquine Sulfate | 379 | $19,954 |
| ProliaDenosumab | 11 | $19,440 |
| MethotrexateMethotrexate Sodium | 430 | $15,368 |
| RasuvoMethotrexate/Pf | 11 | $9,583 |
| Cevimeline Hcl | 41 | $9,517 |
| Leucovorin Calcium | 70 | $9,024 |
| OtrexupMethotrexate/Pf | 11 | $8,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXeljanz | $23,939 | $174,78634 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $25,549 | $133,62121 claims |
| AbbVieRinvoq | $133,056 | $74,91712 claims |
| AmgenProlia | $1,297 | $19,44011 claims |
| Antares Pharma, Inc.Otrexup | $21 | $8,22811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Fountain Hill
- Alan KivitzDuncansville$27.1M
- Peter MerkelRadnor$6.3M
- Rohit AggarwalPittsburgh$6.2M
- Alexis Ogdie-BeattyPhiladelphia$5.7M
- Jonathan MinerPhiladelphia$3.8M
- Siamak Moghadam-KiaPittsburgh$1.9M
- Frederick MurphyDuncansville$1.2M
- Gregory EmkeyWyomissing$1.2M
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.